NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
The stock's fall snapped a three-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback